Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29474439 | 1.00 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL29201750 | 1.00 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL599683 | 1.00 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL1905118 | 0.87 | FABP5 (0.44) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL5233109 | 0.86 | FABP5 (0.43) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL18301546 | 0.86 | GLI1 (0.41) | FABP5FABP7EPHX2 | |
| SCHEMBL5494109 | 0.84 | FABP5 (0.43) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL31054358 | 0.84 | PPARG (0.40) | FABP5FABP7EPHX2KMT2AMDM4 | |
| SCHEMBL28916981 | 0.83 | CHRNB2 (0.40) | FABP5FABP7EPHX2KMT2ACASP3 | |
| SCHEMBL29713658 | 0.83 | CHRNB2 (0.40) | FABP5FABP7EPHX2KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332290-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-10-30 | — | — | US | disclosed |
| EP-4288116-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | Stichting Radboud universitair medisch centrum (NL) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167681-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332290-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | FOLH1, KLK3, PSMA2 | FABP5 206/4885FABP7 218/4885EPHX2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.